. 2022 Apr 18;298(6):101946. doi: 10.1016/j.jbc.2022.101946

Table 2.

Clinical characteristics of patients with NAFLD and healthy subjects

Variables	Control	Non-NASH	NASH
Sample size	314	107	107
Age (years)	43.0±11.9	42.3±11.4	42.5±11.0
Gender (female n, %)	201 (64.0)	21 (19.6)^a	21 (19.6)^a
BMI (kg/m²)^b	21.9 (20.3–24.0)	26.0 (24.5–28.1)^a	27.1 (24.6–29.4)^a
Systolic BP (mmHg)	112.8±11.6	128.1±15.2^a	129.8±14.0^a
Diastolic BP (mmHg)	74.5±10.9	83.4±10.0^a	84.8±10.4^a
Triglycerides (mmol/L)^b	0.90 (0.72–1.19)	1.79 (1.18–2.50)^a	2.18 (1.63–3.10)^a
Total cholesterol (mmol/L)	4.48±0.62	4.89±1.04^a	5.61±1.26^a
LDL-c (mmol/L)	2.50±0.53	2.83±0.79^a	3.24±1.02^a
HDL-c (mmol/L)	1.55±0.38	1.00±0.21^a	0.99±0.20^a
FPG (mmol/L)^b	4.7 (4.4–5.0)	5.2 (4.9–6.0)^a	5.4 (4.9–6.2)^a
HbA1c (%)^b	5.3 (5.1–5.4)	5.8 (5.4–6.6)^a	5.9 (5.4–6.6)^a
HOMA-IR^b	0.79 (0.60–1.04)	1.52 (1.01–2.31)^a	2.20 (1.38–2.06)^a
ALT (U/L)^b	15 (12–20)	39 (25–62)^a	61 (38–90)^a
AST (U/L)^b	19 (17–23)	29 (23–36)^a	38 (27–56)^a
ALP (U/L)	60 (49–72)	74 (63–92)^a	85 (70–96)^a
GGT (U/L)^b	15 (10–21)	44 (27–78)^a	58 (41–109)^a
LIF (pg/ml)^b	8.54 (5.53–12.38)	11.98 (8.62–15.02)^a	13.28 (8.62–17.92)^a

Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body mass index; BP, blood pressure; FGP, fasting plasma glucose; GGT, γ-glutamyl transpeptidase; HbA1c, glycated hemoglobin; HDL-c, high-density lipoprotein cholesterol; HGB, hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-c, low-density lipoprotein cholesterol; LIF, leukemia inhibitory factor; PLT, platelet; RBC, red blood cell; WBC, white blood cell.

Data are presented as the mean ± SD or median (interquartile range).

p< 0.01 compared with control.

Analysis performed on log-transformed data.